Cargando…
The New Extended-Cycle Levonorgestrel-Ethinyl Estradiol Oral Contraceptives
Effective contraceptive counseling requires an understanding of a woman’s preferences and medical history as well as the risks, benefits, side effects, and contraindications of each contraceptive method. Hormonal contraceptives using a variety of delivery methods are highly effective and this review...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888068/ https://www.ncbi.nlm.nih.gov/pubmed/24453511 http://dx.doi.org/10.4137/CMRH.S5030 |
_version_ | 1782299031726194688 |
---|---|
author | Bonnema, Rachel A. Spencer, Abby L. |
author_facet | Bonnema, Rachel A. Spencer, Abby L. |
author_sort | Bonnema, Rachel A. |
collection | PubMed |
description | Effective contraceptive counseling requires an understanding of a woman’s preferences and medical history as well as the risks, benefits, side effects, and contraindications of each contraceptive method. Hormonal contraceptives using a variety of delivery methods are highly effective and this review highlights the new extended-cycle levonorgestrel-ethinyl estradiol contraceptives. Extended-cycle OCPs are unique in offering fewer or no withdrawal bleeds over the course of one year but providers need to carefully counsel women regarding the initial increased breakthrough bleeding. Extended-cycle OCPs may be of particular benefit in women with medical comorbidities who would benefit from less withdrawal bleeds, those desiring to avoid monthly menses due to increased hormonal withdrawal symptoms, or simply women who don’t desire a monthly period. The risks associated with all extended-cycle OCPs have been found to be similar to those of traditional OCPs therefore counseling on the risks and side effects is comparable to that of any combined hormonal contraceptives. Newer extended-cycle regimens shorten or eliminate the hormone-free interval, decrease frequency of menses to four times per year or eliminate menses altogether. This can reduce the risk of common menstrual symptoms, endometriosis, or severe dysmenorrhea by offering potentially greater ovarian suppression and preventing endogenous estradiol production while still providing highly effective, rapidly reversible, and safe contraception. |
format | Online Article Text |
id | pubmed-3888068 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Libertas Academica |
record_format | MEDLINE/PubMed |
spelling | pubmed-38880682014-01-22 The New Extended-Cycle Levonorgestrel-Ethinyl Estradiol Oral Contraceptives Bonnema, Rachel A. Spencer, Abby L. Clin Med Insights Reprod Health Expert Review Effective contraceptive counseling requires an understanding of a woman’s preferences and medical history as well as the risks, benefits, side effects, and contraindications of each contraceptive method. Hormonal contraceptives using a variety of delivery methods are highly effective and this review highlights the new extended-cycle levonorgestrel-ethinyl estradiol contraceptives. Extended-cycle OCPs are unique in offering fewer or no withdrawal bleeds over the course of one year but providers need to carefully counsel women regarding the initial increased breakthrough bleeding. Extended-cycle OCPs may be of particular benefit in women with medical comorbidities who would benefit from less withdrawal bleeds, those desiring to avoid monthly menses due to increased hormonal withdrawal symptoms, or simply women who don’t desire a monthly period. The risks associated with all extended-cycle OCPs have been found to be similar to those of traditional OCPs therefore counseling on the risks and side effects is comparable to that of any combined hormonal contraceptives. Newer extended-cycle regimens shorten or eliminate the hormone-free interval, decrease frequency of menses to four times per year or eliminate menses altogether. This can reduce the risk of common menstrual symptoms, endometriosis, or severe dysmenorrhea by offering potentially greater ovarian suppression and preventing endogenous estradiol production while still providing highly effective, rapidly reversible, and safe contraception. Libertas Academica 2011-09-19 /pmc/articles/PMC3888068/ /pubmed/24453511 http://dx.doi.org/10.4137/CMRH.S5030 Text en © 2011 the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited. |
spellingShingle | Expert Review Bonnema, Rachel A. Spencer, Abby L. The New Extended-Cycle Levonorgestrel-Ethinyl Estradiol Oral Contraceptives |
title | The New Extended-Cycle Levonorgestrel-Ethinyl Estradiol Oral Contraceptives |
title_full | The New Extended-Cycle Levonorgestrel-Ethinyl Estradiol Oral Contraceptives |
title_fullStr | The New Extended-Cycle Levonorgestrel-Ethinyl Estradiol Oral Contraceptives |
title_full_unstemmed | The New Extended-Cycle Levonorgestrel-Ethinyl Estradiol Oral Contraceptives |
title_short | The New Extended-Cycle Levonorgestrel-Ethinyl Estradiol Oral Contraceptives |
title_sort | new extended-cycle levonorgestrel-ethinyl estradiol oral contraceptives |
topic | Expert Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888068/ https://www.ncbi.nlm.nih.gov/pubmed/24453511 http://dx.doi.org/10.4137/CMRH.S5030 |
work_keys_str_mv | AT bonnemarachela thenewextendedcyclelevonorgestrelethinylestradioloralcontraceptives AT spencerabbyl thenewextendedcyclelevonorgestrelethinylestradioloralcontraceptives AT bonnemarachela newextendedcyclelevonorgestrelethinylestradioloralcontraceptives AT spencerabbyl newextendedcyclelevonorgestrelethinylestradioloralcontraceptives |